The interview took place in a US Airways lounge. Amy Mahery was 22, still in college, and carrying a plan that seemed perfectly coherent: graduate, work as an EMT, save money, go to medical school. Across from her sat a regional director whose height and manner she remembered years later. He scanned her resume and found the detail that changed the temperature in the room. He had played rugby. So had she.
He was a forward. Mahery was a fullback for her college team. The exchange helped her win a field-sales job in pharmaceuticals, an outcome she had treated as a practical stop on the way to somewhere else. Then the stop became the road. The industry gave her a way to stay near science, work with people, and solve problems with visible stakes. The aspiring physician found that the commercial side of biopharma had its own anatomy to learn.
That origin story is appealing because it is accidental. The career that followed was anything but. Over more than two decades, Mahery kept choosing assignments that widened her view: sales, brand marketing, pricing, market access, global franchise management, startup incubation, portfolio commercialization and board work. In February 2025, she joined Moderna as senior vice president and chief marketing officer. The title was new. The pattern behind it was already old.
The useful discomfort of the iceberg
Mahery joined EMD Serono in 2004 after her field-sales start at Johnson & Johnson. She spent the next 17 years moving among affiliate and global roles. There was marketing, then payer strategy and contracting, then a return to marketing, then global pipeline work. She did not describe those transitions as a master plan. She described them as a search for depth and breadth.
One nudge came from a trusted colleague. Mahery had already held several commercial positions, but the colleague told her she was operating at the tip of the iceberg. She looked at the market-access lines on the profit-and-loss statement and realized he was right. There was a large part of the business she could see but could not yet explain. So she stepped toward it.
That move mattered because market access sits where many clean internal stories encounter a more complicated outside world. Price, evidence, timing, reimbursement and institutional incentives collide. Mahery learned to treat the commercial question as more than a launch question. It was a development question, a portfolio question and a question about how early a company was willing to confront reality.
“We are all here to learn and grow. Be forgiving of others and yourself.”Amy Mahery's stated philosophy
By November 2019, she was leading global market access and pricing for the healthcare business of Merck KGaA, Darmstadt, Germany. In 2021, she became senior vice president and global franchise head for neurology and immunology at EMD Serono. The sequence is more revealing than either title. Mahery had learned to cross the seam between a product story and the organizational machinery required to support it.
Commercial belongs near the beginning
When Mahery left EMD Serono for Roivant Sciences in August 2022, the change was not simply from a large company to a smaller one. Roivant's hub-and-spoke model asked her to work across a portfolio of focused companies, known as Vants. As the first chief commercial officer at the parent company, she assessed new assets, helped incubate startups, joined their leadership teams, and guided commercialization from the central hub.
The transition forced a useful edit. Large organizations contain specialists for nearly every recurring problem. In a biotech startup, Mahery observed, resources are thin. An executive rolls up her sleeves, leans on a reciprocal network, and decides which parts of the familiar playbook are essential. Her formulation was blunt: the biggest decisions matter; everything else may be incremental and optional.
This is where her idea of marketing becomes interesting. Mahery does not reduce commercial work to advertising, a sales force or a final burst of launch activity. She describes it as asset strategy. The commercial perspective should arrive while a program's vision is being formed, because the decisions made early constrain everything that follows. Her answer to when to hire commercial talent was only four words: “As soon as possible.”
Invite the downstream operator into the upstream decision. Ask about adoption, access and delivery while the plan is still cheap to change.
The principle travels well beyond biopharma. Product teams benefit when distribution is considered before a product is finished. Editorial teams benefit when packaging is discussed before publication. Founders benefit when customer behavior enters the room before the roadmap hardens. Mahery's version comes from a regulated, capital-intensive business, but the mechanism is ordinary: involve the people who will live with a decision while the decision is still reversible.
Give people the room, not just the memo
Mahery's most practical leadership idea may also be the least expensive. Let developing leaders sit in on leadership meetings. They hear which facts change a decision, where uncertainty lives, and how experienced operators disagree without losing the thread. The room becomes a classroom.
Her phrase for the effect is “democratizes information.” That is more precise than generic transparency. A document can share a conclusion. Access to the discussion shares the reasoning. It allows someone earlier in a career to see how a senior team weighs timing, evidence, capital and organizational capacity. The person leaves with more than an answer; she leaves with a better model for producing one.
“Let's be transparent so that people can learn.”Amy Mahery on developing talent
This instinct fits her own biography. Mahery advanced by entering rooms where she did not yet know the language: first a sales territory, then market access, then global pricing, then the startup portfolio. Her leadership method gives others a less lonely version of the same education. It turns context into a shared asset.
There is also a personal note in the way she talks about motivation. Most people, she has said, want to make an important impact. A manager's job is partly to learn what form that desire takes, then connect it to the work. That requires curiosity about people, not merely a system for ranking them.
The science student stays in the frame
Mahery earned a Bachelor of Science in neuroscience from Trinity College-Hartford. She has described herself as fascinated by living systems from childhood, whether watching medically themed television or exploring the woods behind her house. That curiosity did not lead to the white coat she once imagined, but it never left the work.
At Roivant, broad scientific fluency helped her move among different programs without attaching her identity to a single category. At Pulmovant, a company within the Roivant portfolio, she shifted from the central hub into a full-time chief commercial officer role after helping with diligence and startup work. The move showed the same tendency as the old market-access switch: when an unfamiliar part of the business became consequential, she got closer.
Her 2024 appointment to the board of CNS Pharmaceuticals added another perspective. A board seat requires commercial experience to be translated into questions, oversight and judgment rather than direct execution. It widened the frame again.
Then came Moderna. In announcing the move, Mahery emphasized the bridge between commercial strategy and R&D. She wrote about expanding access, shaping the pipeline and creating value across several constituencies. The language was consistent with the career underneath it. Marketing, in this view, is not a decorative layer applied to completed science. It is one of the disciplines that helps a scientific organization decide what it can responsibly build and deliver.
Range before rank
Executive biographies can make careers look inevitable. A row of titles smooths away the moments when the person did not know the next step, entered a function as a beginner, or followed an affinity that only became obvious through the work. Mahery's story is more useful with the seams left visible.
There was the ice-cream-shop waitress who became a college rugby fullback. The future medical student who accepted a sales job. The marketer who admitted she understood only the tip of the business. The Big Pharma leader who entered a startup model and found herself doing work she had not touched in years. The portfolio executive who moved into one of the companies she had helped incubate. None of those transitions erased the previous identity. Each added another operating lens.
Her career offers a quiet correction to the straight-ladder fantasy. Rank matters because it carries responsibility. Range matters because it helps a leader see where that responsibility travels. Mahery built the second before receiving more of the first.
The rugby conversation in the airport lounge makes a good opening scene, but the better lesson comes afterward. Chance opened a door. Mahery kept walking through the doors that required her to learn a new room.